GT
KPTI icon

Glenmede Trust’s Karyopharm Therapeutics KPTI Stock Holding History

Glenmede Trust’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-193
Closed -$42K – 1761
2020
Q3 		$42K Buy
193
+90
+87% +$22K ﹤0.01% 1375
2020
Q2 		$29K Buy
+103
New +$30.5K ﹤0.01% 1457

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Glenmede Trust's KPTI Position: Q4 2020 in Review

Glenmede Trust sold out of Karyopharm Therapeutics (KPTI) in Q4 2020, closing a stake of 193 shares — an estimated $42K sold.

Glenmede Trust first reported a position in KPTI in Q2 2020 and held it in 2 quarters. The position peaked at $42K in Q3 2020. 168 funds tracked by Wall St. Rank hold KPTI as of Q4 2020.

  • Glenmede Trust reported no remaining Karyopharm Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 193 Karyopharm Therapeutics shares in Q4 2020, an estimated $42K.
  • Glenmede Trust first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's Karyopharm Therapeutics position peaked at $42K in Q3 2020.
  • 168 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.